EQ
HEALTHCAREEquillium Inc
$2.17+0.10 (+4.83%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving EQ Today?
No stock-specific AI insight has been generated for EQ yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.27$2.70
$2.17
Fundamentals
Market Cap$137M
P/E Ratio—
EPS$-0.39
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume185K
Avg Volume (10D)—
Shares Outstanding63.2M
EQ News
18 articles- Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 1, 2026
- Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island EventYahoo Finance·Apr 20, 2026
- Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of ImmunologistsYahoo Finance·Apr 8, 2026
- Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical HighlightsYahoo Finance·Mar 25, 2026
- Here’s What Roth Capital Thinks of Equillium (EQ) StockYahoo Finance·Mar 24, 2026
- Equillium to Participate in the 38th Annual Roth ConferenceYahoo Finance·Mar 18, 2026
- Equillium Announces $35 Million Financing with RA Capital ManagementYahoo Finance·Mar 13, 2026
- Equillium to Participate in the Leerink Partners 2026 Global Healthcare ConferenceYahoo Finance·Feb 25, 2026
- Equillium Conference: EQ504 Targets Ulcerative Colitis Ahead of Mid-Year Phase 1 StartMarketbeat·Feb 13, 2026
- Equillium to Participate in Upcoming Investor ConferencesYahoo Finance·Nov 20, 2025
- Equillium Reports Third Quarter 2025 Financial Results and Provides Operational UpdateYahoo Finance·Nov 13, 2025
- Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025Yahoo Finance·Oct 22, 2025
- Equillium Announces Leadership and Corporate UpdatesYahoo Finance·Oct 6, 2025
- Equillium to Participate in the Cantor Global Healthcare Conference 2025Yahoo Finance·Aug 29, 2025
- Trending tickers: Intel, Tilray, monday.com, Equillium and AMCYahoo·Aug 12, 2025
- BC-Most Active StocksYahoo Finance·Aug 11, 2025
- Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the ClinicYahoo Finance·Aug 11, 2025
- Spotlight On 3 Promising Penny Stocks With Over $20M Market CapYahoo Finance·Aug 4, 2025
All 18 articles loaded
Price Data
Open$2.13
Previous Close$2.07
Day High$2.16
Day Low$2.03
52 Week High$2.70
52 Week Low$0.27
52-Week Range
$0.27$2.70
$2.17
Fundamentals
Market Cap$137M
P/E Ratio—
EPS$-0.39
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume185K
Avg Volume (10D)—
Shares Outstanding63.2M
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory or immuno-inflammatory disorders with unmet medical needs. The company is headquartered in La Jolla, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—